Trial · NCT01010750
Participant flow54
How many started, completed or left each group, period by period.
1 to 20 of 54
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| First Intervention | STARTED | LDX 50 mg First, Then MAS-IR 20 mg, Then Placebo | 3 | |
| First Intervention | STARTED | LDX 50 mg First, Then Placebo, Then MAS-IR 20 mg | 4 | |
| First Intervention | STARTED | Placebo First, Then LDX 50 mg, Then MAS-IR 20 mg | 3 | |
| First Intervention | STARTED | Placebo First, Then MAS-IR 20 mg, Then LDX 50 mg | 3 | |
| First Intervention | STARTED | MAS-IR 20 mg First, Then LDX 50 mg, Then Placebo | 2 | |
| First Intervention | STARTED | MAS-IR 20 mg First, Then Placebo, Then LDX 50 mg | 3 | |
| First Intervention | COMPLETED | LDX 50 mg First, Then MAS-IR 20 mg, Then Placebo | 3 | |
| First Intervention | COMPLETED | LDX 50 mg First, Then Placebo, Then MAS-IR 20 mg | 4 | |
| First Intervention | COMPLETED | Placebo First, Then LDX 50 mg, Then MAS-IR 20 mg | 3 | |
| First Intervention | COMPLETED | Placebo First, Then MAS-IR 20 mg, Then LDX 50 mg | 3 | |
| First Intervention | COMPLETED | MAS-IR 20 mg First, Then LDX 50 mg, Then Placebo | 2 | |
| First Intervention | COMPLETED | MAS-IR 20 mg First, Then Placebo, Then LDX 50 mg | 3 | |
| First Intervention | NOT COMPLETED | LDX 50 mg First, Then MAS-IR 20 mg, Then Placebo | 0 | |
| First Intervention | NOT COMPLETED | LDX 50 mg First, Then Placebo, Then MAS-IR 20 mg | 0 | |
| First Intervention | NOT COMPLETED | Placebo First, Then LDX 50 mg, Then MAS-IR 20 mg | 0 | |
| First Intervention | NOT COMPLETED | Placebo First, Then MAS-IR 20 mg, Then LDX 50 mg | 0 | |
| First Intervention | NOT COMPLETED | MAS-IR 20 mg First, Then LDX 50 mg, Then Placebo | 0 | |
| First Intervention | NOT COMPLETED | MAS-IR 20 mg First, Then Placebo, Then LDX 50 mg | 0 | |
| Second Intervention | STARTED | LDX 50 mg First, Then MAS-IR 20 mg, Then Placebo | 3 | |
| Second Intervention | STARTED | LDX 50 mg First, Then Placebo, Then MAS-IR 20 mg | 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01010750/flow